XML 28 R42.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCKHOLDERS' EQUITY (Details Narrative) (USD $)
 0 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 9 Months Ended 27 Months Ended 3 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
Oct. 02, 2011
Dec. 31, 2012
Dec. 31, 2011
Oct. 03, 2011
Jul. 29, 2011
Jul. 28, 2011
Dec. 31, 2010
Dec. 31, 2012
2009 Long Term Incentive Compensation Plan
Dec. 31, 2012
2012 Stock Incentive Plan
Dec. 31, 2012
Company Warrants
Dec. 31, 2011
Company Warrants
Dec. 31, 2012
Company Warrants
Services
Dec. 31, 2011
Company Warrants
Services
Dec. 31, 2012
Company Warrants
Services - VitaMed Contract
Dec. 31, 2011
Company Warrants
Services - VitaMed Contract
Dec. 31, 2011
Company Warrants
Services Provided in October 2011
Dec. 31, 2011
Company Warrants
Services Provided in December 2011
Dec. 31, 2012
Company Warrants
Lower Range
Dec. 31, 2011
Company Warrants
Lower Range
Dec. 31, 2011
Company Warrants
Lower Range
Services
Dec. 31, 2012
Company Warrants
Upper Range
Dec. 31, 2011
Company Warrants
Upper Range
Dec. 31, 2011
Company Warrants
Upper Range
Services
Dec. 31, 2012
Warrants Issued in March 2012
Services
Dec. 31, 2012
Warrants Issued in May 2012
Services
Dec. 31, 2012
Warrants Issued in June 2012
Services
Dec. 31, 2011
VitaMed Warrants
Services - VitaMed Contract
Dec. 31, 2012
Warrant1Member
Services Provided in October 2011
Lang
Dec. 31, 2011
Warrant1Member
Services Provided in October 2011
Lang
Oct. 03, 2011
VitaMed Stock Options
Dec. 31, 2010
VitaMed Stock Options
Dec. 31, 2011
Company Options
Dec. 31, 2012
Company Options
Dec. 31, 2011
Company Options
Dec. 31, 2010
Company Options
Dec. 31, 2012
Company Options
Lower Range
Dec. 31, 2011
Company Options
Lower Range
Dec. 31, 2012
Company Options
Upper Range
Dec. 31, 2011
Company Options
Upper Range
Oct. 05, 2011
Stock Purchase Agreement with Pernix Therapeutics
Dec. 31, 2012
February 24 Debt Issuance
Dec. 31, 2012
June 19 Debt Issuance
Dec. 31, 2012
June 19 Debt Issuance
Warrants Tranche 2
Dec. 31, 2012
June 19 Debt Issuance
Warrants Tranche 1
Dec. 31, 2012
March 2011 Line of Credit
Company Warrants
Dec. 31, 2012
VitaMed Promissory Note June 2011
Dec. 31, 2011
VitaMed Promissory Note June 2011
Dec. 31, 2012
VitaMed Promissory Note June 2011
Company Warrants
Dec. 31, 2012
VitaMed Promissory Note June 2011
VitaMed Warrants
Dec. 31, 2012
VitaMed Promissory Note June 2011
VitaMed Warrants
Lower Range
Dec. 31, 2012
VitaMed Promissory Note June 2011
VitaMed Warrants
Upper Range
Dec. 31, 2012
Company Warrants
Services
Company Officer
Dec. 31, 2011
Company Warrants
Services
Company Officer
Preferred stock, shares authorized   10,000,000 10,000,000                                                                                                    
Preferred stock, par value   $ 0.001 $ 0.001                                                                                                    
Common stock, shares authorized   250,000,000 250,000,000   250,000,000                                                                                                
Common stock, par value   $ 0.001 $ 0.001                                                                                                    
Common stock, shares issued   99,784,982 82,978,804                                                                                                    
Common stock, shares outstanding   99,784,982 82,978,804 58,573,187 165,856 16,575,209 55,487,321                                                                                            
Shares issued for exercise of options   $ 191,000                                                                                                      
Shares issued for exercise of options, shares   1,931,788                                                             (1,931,788) (92,057)                                      
Noncash options exercised shares forfeited in lieu of cash   26,428                                                                                                      
Noncash options exercised net options received   240,395                                                                                                      
Shares issued in exercise of warrants   3,102,000 17,250                                                                           3,102,000                        
Shares issued in exercise of warrants, shares   8,145,486 92,057                                                                           8,145,486                        
Value of debt converted to shares   1,054,647 849,137                                                                                     1,054,647 1,054,647            
Shares issued in exchange for debt, shares   2,775,415 21,681,958                                                                                     2,775,415 2,775,415            
Conversion Price Per share   $ 0.38                                                                                       $ 0.38 $ 0.38            
Shares issued in private placement   7,895,485 1,707,000                                                                         1,000,000                          
Shares issued in private placement, shares   3,953,489 5,551,589                                                                         2,631,579                          
Cash fees paid to private placement agent   552,500                                                                                                      
Legal fees paid for investors in private placement   52,016                                                                                                      
Price per share of common stock issued in private placement   $ 2.15                                                                                                      
Aggregate purchase price of common stock sold in private placement   8,500,001                                                                                                      
Stock Purchase Price                                                                               $ 0.38                          
Reverse split description 1 for 100                                                                                                        
Warrants outstanding   12,193,499               12,193,499                                                                                      
Weighted average contractual life                   4 years 9 months 18 days 7 years 10 months 24 days                                                                                    
Exercise Price                   $ 1.63                $ 0.24     $ 3.00                     $ 0.16 $ 1.16 $ 0.16 $ 0.16 $ 2.20 $ 0.10 $ 3.40 $ 1.22                            
Unamortized costs warrants                   93,000                                                                                      
Warrants Issued                                                                                         613,713   613,718 613,718 500,000        
Warrants Issued - Note Modification                                                                                 5,685,300 7,000,000 1,000,000 6,000,000                  
Warrants Issued - new Funding                                                                                 3,314,700       0.2444                
Exercise Price per share of warrants issued                                                                                 $ 0.38   $ 3.00 $ 2.00                  
Fair Value Modification Warrants Issued February 2012                                                                                 10,505,247                        
FV Warrants Issued - new Funding                                                                                 6,124,873                        
Valuation Method                   Black-Scholes Black-Scholes                         Black-Scholes Method Black-Scholes Method Black-Scholes Method                             Black-Scholes Method Black-Scholes Method                      
Expected term                   5 years 7 years 10 months 24 days 5 years       5 years 10 years   5 years 5 years   10 years 10 years 5 years 5 years 5 years 5 years   10 years             5 years 5 years 6 months 6 years 3 months 6 years 3 months   5 years 5 years     10 years       5 years       5 years
Expected Volatility                               41.04% 51.83% 44.64% 39.13%   44.81% 51.83%   44.81% 44.71% 44.78% 39.44%   45.94%             40.77% 37.92% 46.01% 40.48%   44.50% 44.64%     47.89%         39.13% 39.15%   45.94%
Risk-free interest rate                               1.08% 0.91% 0.72% 0.91%   1.04% 3.48%   1.04% 0.74% 0.72% 1.56%   2.23%             0.61% 0.91% 2.23% 2.54%   0.89% 0.75%     3.48%         1.38% 1.65%   2.23%
Expected dividend yield                   0.00%           0.00% 0.00%   0.00%         0.00% 0.00% 0.00% 0.00%   0.00%       0.00% 0.00%             0.00% 0.00%     0.00%       0.00%       0.00%
Debt discount on notes payable   1,102,680 0                                                                           859,647 1,102,680       28,719     30,993        
Amortization of debt discount   1,604,240 28,719                                                                           859,647 547,210                      
Warrants Fair Value                   27,618,722 474,267 1,563,620 159,363     25,980 338               1,532,228   12,548                             9,424,982     86,139               133,045
Fair value on grant date                                                                                   1,649,890                      
Warrants issued for consulting services                             245,485 184,211 500             31,000 1,300,000 1,500 200,000   800,000                                               600,000
Awards issued for services, professional fees recognized                           6,936 5,612   15             29,736 218,045 1,656   88,696 17,010                                             36,284 7,158
Prepaid Consulting Expense, Short Term                                 323               360,528     71,688 160,384                                                
Prepaid Consulting Expense, Long Term                                                 953,655                                                        
Warrants vesting terms                                                                                         Awards vest 76,714 shares per calendar quarter end             vests over a 44-month period beginning on November 21, 2011 (or 13,36 shares for months 1-43 and 13,652 shares for month 44) vests over a 44-month period beginning on November 21, 2011 (or 13,36 shares for months 1-43 and 13,652 shares for month 44)
Repayment of bank line of credit   (300,000)                                                                                                       
Warrants vested                                                                                         562,571                
Loan guaranty costs   (45,036) (38,159)                                                                                                    
Warrant cost to be recognized                                                                                                       89,603  
Shares authorized under incentive plan         25,000,000     25,000,000 10,000,000                                                                                        
Shares issued under incentive plans               11,508,488 2,225,000                                             10,590,161 13,733,488 10,590,161                                       
Awards Granted                                                           762,235 9,357,561 562,422 5,121,250 [1] 10,682,218 [1]                                      
VitaMed options cancelled                                                             16,000                                            
VitaMed Options                                                           621,000 7,639,722                                            
Weighted average grant date fair value of options granted   $ 1.16 $ 0.16                                                                                                    
Share based compensation expense   1,868,345 190,513                                                           1,832,062 183,355                                      
Unrecognized estimated compensation expense   $ 4,391,000 $ 244,000                                                                                                    
Period for recognition of remaining unrecognized compensation expense   1 year 9 months 18 days                                                                                                      
[1] This includes: (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units of which 16,000 were canceled prior to conversion (or Company Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Company Options for 762,235 shares per the Conversion Ratio) and (iii) Company Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Company Options including the number of shares vested.